Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer

• Status: Completed
• Trial end date: 2004-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

This trial will evaluate the effectiveness of standard adjuvant treatment with CMF chemotherapy versus treatment with weekly docetaxel in patients with high-risk breast cancer who are 65 years of age and older or are poor candidates for anthracycline-containing regimens. This CMF regimen has decreased dose intensity and may be slightly less active in patients with metastatic breast cancer; however, the patient population in this trial has tolerated more intensive CMF regimens poorly in other trials.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SCRI Development Innovations, LLC
• Collaborator: Aventis Pharmaceuticals
• Treatments: Cyclophosphamide; Docetaxel; Fluorouracil; Methotrexate

Criteria

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

• Female patients with adenocarcinoma of the breast confirmed by biopsy

• Age 65 or older

• Under age 65 must have significant medical illness, or general frailty

• Adequate bone marrow, liver or kidney function

• Normal heart function

• Less than 84 days from mastectomy/lumpectomy or axillary dissection

• Signed consent obtained prior to initiation of any study procedures

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

• Received neo-adjuvant therapy

• Primary tumor is locally advanced at diagnosis

• Received prior chemotherapy within five years

• Received previous radiation therapy within 5 years

• Peripheral neuropathy

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.